Predicting the risk of relapse in polymyalgia rheumatica: novel insights

References

• González-Gay MA, Matteson EL, Castañeda S Polymyalgia rheumatica. Lancet 2017; 390:1700–1712.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347:261–271.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61:1454–1461.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Rodríguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rateA more benign syndrome. Arch Intern Med 1997;157:317–320.
   PubMedGoogle Scholar
• Manzo C, Milchert M Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosis: a four-point guidance. Reumatologia 2018; 56:1–2.
   PubMedGoogle Scholar
• Gonzalez-Gay MA Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004; 33:289–293.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Vázquez-Caruncho M Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998; 25:1750–1755.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000; 27:2179–2184.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European league against rheumatism/American college of rheumatology collaborative initiative. Arthritis Rheum 2012;64:943–954.
   Web of Science ®Google Scholar
• Mackie SL, Twohig H, Neill LM, et al. The OMERACT core domain set for outcome measures for clinical trials in polymyalgia rheumatica. J Rheumatol 2017;44:1515–1521
   PubMed Web of Science ®Google Scholar
• Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European league against rheumatism/American college of rheumatology collaborative initiative. Arthritis Rheumatol 2015; 67: 2569–2580
   PubMed Web of Science ®Google Scholar
• Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European league against rheumatism/American college of rheumatology collaborative initiative. Ann Rheum Dis 2015; 74: 1799–1807
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Pina T Giant cell arteritis and polymyalgia rheumatica: anupdate. Curr Rheumatol Rep 2015; 17: 6.
   PubMed Web of Science ®Google Scholar
• Matteson EL, Buttgereit F, Dejaco C, et al. Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis. Rheum Dis Clin North Am 2016; 42: 75–90.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Castañeda S Managing of giant cell arteritis and polymyalgia rheumatica. Expert Opin Orphan Drugs 2016; 4: 1133–1144.
   Web of Science ®Google Scholar
• Healey LA Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13:322–328.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Salvarani C, et al. Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18:755–759.
   PubMed Web of Science ®Google Scholar
• Prieto-Peña D, Martínez-Rodríguez I, Loricera J, et al. Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. Semin Arthritis Rheum 2019; 48: 720–727.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Prieto-Peña D, Martínez-Rodríguez I, et al. Early large vessel systemic vasculitis in adults. Best Pract Res Clin Rheumatol 2019; 33: 101424.
   PubMed Web of Science ®Google Scholar
• Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population-based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005; 32:65–73.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26:1326–1332.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Duftner C, Cimmino MA, et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis 2011; 70: 447–453.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective follow-up study. Arthritis Rheum 2005; 53: 33–38
   PubMed Web of Science ®Google Scholar
• Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97:672–680.
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30:17–24.
   PubMed Web of Science ®Google Scholar
• Bengtsson BA, Malmvall BE Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumaticaA follow-up study on ninety patients treated with corticosteroids. Acta Med Scand 1981; 209:337–345.
   PubMedGoogle Scholar
• Von Knorring J Treatment and prognosis in polymyalgia rheumatica and temporal arteritisA ten-year survey of 53 patients. Acta Med Scand 1979; 205:429–435.
   PubMedGoogle Scholar
• Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010;49:186–190.
   PubMed Web of Science ®Google Scholar
• Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 2011; 90:186–193
   PubMed Web of Science ®Google Scholar
• Liozon E, De Boysson H, Dalmay F, et al. Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study. J Rheumatol 2018; 45:678–685
   PubMed Web of Science ®Google Scholar
• Narvaez J, Estrada P, López-Vives L, et al. Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica. Semin Arthritis Rheum 2015; 45: 328–333.
   PubMed Web of Science ®Google Scholar
• Leeb BF, Rintelen B, Sautner J, et al. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 2007;57:810–815
   PubMed Web of Science ®Google Scholar
• Binard A, De Bandt M, Berthelot JM, et al. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 2008;59:263–269 28D.
   PubMed Web of Science ®Google Scholar
• Hernández-Rodríguez J, Cid MC, López-Soto A, et al. Treatment of polymyalgia rheumatica A systematic review. Arch Intern Med 2009; 169: 1839–1850.
   PubMedGoogle Scholar
• Behn AR, Perera T, Myles AB Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 1983; 42: 374–378.
   PubMed Web of Science ®Google Scholar
• Kyle V, Hazleman BL The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993; 52: 847–850.
   PubMed Web of Science ®Google Scholar
• Narváez J, Nolla-Solé JM, Clavaguera MT, et al. Long-term therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol 1999; 26:1945–1952.
   PubMed Web of Science ®Google Scholar
• Lee JH, Choi ST, Kim JS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 2013; 33:1475–1480.
   PubMed Web of Science ®Google Scholar
• Smutny T, Barvik I, Veleta T, et al. Genetic predispositions of glucocorticoid resistance and therapeutic outcomes in polymyalgia rheumatica and giant cell arteritis. J Clin Med 2019; 8: 582.
   Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002; 31:355–360.
   PubMed Web of Science ®Google Scholar
• Boiardi L, Casali B, Farnetti E, et al. Relationship between interleukin 6 promoter polymorphism at position −174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 2006; 33:703–708.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Amoli MM, Garcia-Porrua C, et al. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003; 33:38–48.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Casali B, Boiardi L, et al. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2000; 27:1215–1221.
   PubMed Web of Science ®Google Scholar
• Amoli MM, Shelley E, Mattey DL, et al. Intercellular adhesion molecule-1 gene polymorphisms in isolated polymyalgia rheumatica. J Rheumatol 2002; 29:502–504.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. Corticotropin releasing hormone promoter polymorphisms in giant cell arteritis and polymyalgia rheumatica. Clin Exp Rheumatol 2002; 20:133–138.
   PubMed Web of Science ®Google Scholar
• Van Sleen Y, Boots AMH, Abdulahad WH, et al. High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. Rheumatology 2020; 59: 176–184.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Pina T, Prieto-Peña D, et al. Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. Expert Opin Pharmacother 2018; 19:1235–1244.
   PubMed Web of Science ®Google Scholar
• Castañeda S, García-Castañeda N, Prieto-Peña D, et al. Treatment of polymyalgia rheumatica. Biochem Pharmacol. 2019; 165: 221–229
   PubMed Web of Science ®Google Scholar
• Van Der Veen MJ, Dinant HJ, Van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996; 55: 218–223.
   PubMed Web of Science ®Google Scholar
• Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004; 141: 493–500.
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996; 23:624–628.
   PubMed Web of Science ®Google Scholar
• Ruediger C, Nguyen L, Black R, et al. Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care. Intern Med J 2020; 50:1067–1072.
   PubMed Web of Science ®Google Scholar
• De La Torre ML, Rodríguez AM, Pisoni CN Usefulness of methotrexate in the reduction of relapses and recurrences in polymyalgia rheumatica: an observational study. J Clin Rheumatol 2020; 26:S213–S217.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Hetland H, Myklebust G Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int 2013;2013:120638.
   PubMed Web of Science ®Google Scholar
• Adizie T, Christidis D, Dharmapaliah C, et al. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract 2012; 66:906–909.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017; 377:317–328.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum 2015; 44:717–723.
   PubMed Web of Science ®Google Scholar
• Calderón-Goercke M, Loricera J, Aldasoro V, et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum. 2019; 49: 126–135.
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis 2016; 75:1506–1510.
   PubMed Web of Science ®Google Scholar
• Lally L, Forbess L, Hatzis C, et al. Brief report: a prospective open-label phase iIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 2016; 68: 2550–2554
   PubMed Web of Science ®Google Scholar
• Akiyama M, Kaneko Y, Takeuchi T Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum. 2020; 50: 521–525.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Llorca J Clinical guidelines: best practices and uncertainties in the management of PMR. Nat Rev Rheumatol 2016; 12: 3–4.
   PubMed Web of Science ®Google Scholar